Variation of fibrinogen oligosaccharide structure in the acute phase response: Possible haemorrhagic implications

BBA Clinical

Volumn 3, Issue , 2015, Pages 221-226

  Brennan, Stephen O ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Acute phase response; Effects on coagulation; Fibrinogen; Oligosaccharide structure changes; Whole protein mass spectrometry

Indexed keywords

ACUTE PHASE PROTEIN; ASIALOGLYCOPROTEIN RECEPTOR; BETA GALACTOSIDASE; C REACTIVE PROTEIN; FIBRIN MONOMER; FIBRINOGEN; GALACTOSE; GLYCOPEPTIDASE; GLYCOPEPTIDE; GLYCOSIDASE; OLIGOSACCHARIDE; SIALIC ACID;

ACUTE PHASE RESPONSE; ADULT; ARTICLE; BLEEDING DISORDER; CASE REPORT; ELECTROSPRAY MASS SPECTROMETRY; GENE MAPPING; GENETIC VARIABILITY; HUMAN; LUNG ABSCESS; MALE; MIDDLE AGED; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN ISOLATION; PROTEIN PURIFICATION; PROTEIN STRUCTURE; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STRUCTURAL HOMOLOGY;

EID: 84924668251     PISSN: 22146474     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbacli.2015.02.007     Document Type: Article

References (23)

1. Tennent G.A., Brennan S.O., Stangou A.J., O'Grady J., Hawkins P.N., Pepys M.P. Human plasma fibrinogen is synthesized in the liver. Blood 2007, 109:1971-1974.
2. Huang S., Cao Z., Chung D.W., Davies E.W. The role of βγ and αγ complexes in the assembly of human fibrinogen. J. Biol. Chem. 1996, 271:27942-27947.
3. Townsend R.R., Hilliker E., Li Y.-T., Laine R.A., Bell W.R., Lee Y.C. Carbohydrate structure of human fibrinogen. J. Biol. Chem. 1982, 257:9704-9710.
4. Mizuochi T., Taniguchi T., Asami Y., Takamatsu J., Okude M., Iwanaga S., Kobata A. Comparative studies on the structure of the carbohydrate moieties of human fibrinogen and abnormal fibrinogen Nagoya. J. Biochem. 1982, 92:283-293.
5. Brennan S.O., Roncolato F. Novel fibrinogen (Bβ401Gly→Val) presents as dys- or hypodysfibrinogenaemia due to alterations in sialic acid content. Thromb. Haemost. 2011, 106:551-553.
6. Martinez J., MacDonald K.A., Palascak J.E. The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains. Blood 1983, 61:1196-1202.
7. Sørensen A.L., Rumjantseva R., Nayeb-Hashemi S., Clausen H., Hartwig J.H., Wandall H.H., Hoffmeister K.M. Role of sialic acid for platelet life span: exposure of β-galactose results in the rapid clearance of platelets from the circulation by asialoglycoprotein receptor-expressing liver macrophages and hepatocytes. Blood 2009, 114:1645-1654.
8. Brennan S.O. Electrospray ionisation analysis of human fibrinogen. Thromb. Haemost. 1997, 78:1055-1058.
9. Maghzal G.J., Brennan S.O., George P.M. Sialic acid content of fibrinogen; effect of pregnancy and fibrate therapy. Thromb Res. 2005, 115:293-299.
10. Carrell R.W., Jeppsson J.-O., Laurell C.-B., Brennan S.O., Owen M.C., Vaughan L., Boswell D.R. Structure and variation of human α1-antitrypsin. Nature 1982, 298:329-334.
11. Holm B., Godal H.C. Quantitation of the three normally-occurring plasma fibrinogens in health and during so-called "acute phase" by SDS electrophoresis of fibrin obtained from EDTA-plasma. Thromb Res. 1984, 35:279-290.
12. Seydewitz H.H., Witt I. Increased phosphorylation of human fibrinopeptide A under acute phase conditions. Thromb Res. 1985, 40:29-39.
13. Haglund A.C., Ronquist G., Frithz G.Ek P. Alterations of the fibrinogen molecule and its phosphorylation state in myocardial infection patients undergoing thrombolytic treatment. Thromb Res. 2000, 98:147-156.
14. Karlsson M., Ternstrom L., Hyllner M., Baghaei F., Flinck A., Skrtic S., Jeppsson A. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery. A prospective randomised pilot study. Thromb. Haemost. 2009, 102:137-144.
15. Jensen T., Halvorsen S., Goda H.C., Sandset P.M., Skjùnsberg O.H. Discrepancy between fibrinogen concentrations determined by clotting rate and clottability assays during the acute-phase reaction. Thromb Res. 2000, 100(1):397-403.
16. Preston R.J.S., Rawley O., Gleeson E.M., O'Donnell J.S. Elucidating the role of carbohydrate determinants in regulating haemostasis: insights and opportunities. Blood 2013, 121:3801-3810.
17. Schmidt D., Brennan S.O. Modified form of the fibrinogen Bβ chain (des-Gln Bβ): a potential long term marker of pancreatitis. Clin. Chem. 2007, 53:2105-2211.
18. Brennan S.O., Mangos H., Faed J. Benign FGB (148Lys→Asn, and 448Arg→Lys), and novel causative γ211Tyr→His mutation distinguished by time of flight mass spectrometry in a family with hypofibrinogenaemia. Thromb. Haemost. 2014, 111:679-684.
19. Brennan S.O., George P.M., Jordan R.E. Physiological variant of antithrombin-III lacks carbohydrate side chain at Asn 135. FEBS Lett. 1987, 219:431-443.
20. Pol-Fachin L., Becker C.F., Guimaraes J.A., Verli H. Effects of glycosylation on heparin binding and antithrombin activation by heparin. Proteins Struct. Funct. Bioinforma. 2011, 7:2735-2745.
21. Sodetz M., Pizzo S.V., McKee P.A. Relationship of sialic acid to function and in vivo survival of human factor VIII/von Willebrand factor protein. J. Biol. Chem. 1977, 252:5538-5546.
22. Ellies L.G., Ditto D., Levy G.G., Wahrenbrock M., Ginsburg D., Varki A., Le D.T., Marth J.D. Sialyltransferase ST3Gal-IV operates as a dominant modifier of hemostasis by concealing asialoglycoprotein receptor ligands. PNAS 2002, 99:10042-10047.
23. Diaz-Maurino T., Albert A.Castro C. Desialylation of fibrinogen with neuraminidase. Kinetic and clotting studies. Thromb Res. 1982, 27:397-403.